Nimetumia neno msukule kwa makusudi maalumu. Msukule sio tusi ni nomino, ni jina la mtu aliyetekwa nyara kiroho na kupotezwa kimazingara.
Kwanini madaktari ni misukule? Nitafafanua kwa ufupi na kwa kiwango kinachoeleweka.
Madaktari wengi akili zao zimefungwa minyororo, hawana wazo huru, wala hawana ujuzi huru. Wamebeba furushi la elimu ya kukaririshwa na kumezeshwa kama makinda ya bundi-mwitu.
Nikizungumza daktari, kwa muktadha wa kitanganyika, namaanisha watu wote wanaojiita wataalamu wa sayansi ambao kimsingi wala sio wataalamu, wengi wao wana diploma za D mbili kisha wakaunga unga mpaka Kairuki University au Bugandooh kisha wakavaa makoti meupe wakaanza kujiita madaktari na wanasayansi.
Kiukweli wako mbali sana na sayansi. Hawaijui wala hawaielewi sayansi. Ukimuuliza daktari wa kitanganyika kwanini kansa haina dawa anakwambia kansa haina dawa kwa sababu mabeberu hawajaleta chanjo.
Mfumo mzima wa daktari wa kitanganyika umejengwa katika muhimili wa kukariri na kusubiri maagizo ya mabeberu.
Beberu likiamuru kwamba kansa haina dawa basi ujue daktari wa kitanganyika hapindui meza. Ni mwendo wa kansa haina dawa hadi pale beberu litakapoamua vinginevyo.
Huu ni msukule wa kitanganyika katika mavazi meupe. Akili imefungwa minyororo ya chuma.
Corona ilituaibisha. Wanasayansi wetu wa kitanganyika walijificha uvunguni wakisubiri kuokolewa na mabeberu. Alhamdulillah mabeberu wakatutupia magunia ya chanjo tuyafakamie tupendavyo.
MY TAKE: Madaktari wote wafutiwe leseni zao wakawe wachimbaji wa kawaida wa mitaro ya barabara.
Una pointi, lakini kabla ya kurusha haya malalamiko sina uhakika kama umefanya ufuatiliaji wowote.
Nakubali kutokufanya vyema kwa sekta ya afya, matatizo ni mtambuka.
Mtaalamu wa afya yoyote, hawezi kutumia utaalamu aliougundua pekee. Bali atatumia na waliyoyagundua wenzie na yakapitishwa kitaalamu kwa kukidhi vigezo.
Si kosa kutumia ugunduzi wa sehemu nyingine kwenye kupata suluhusho la tatizo la msingi katika nyanja yoyote.
Kuhusu utafiti wa dawa au vifaa tiba:
1: Hii ni kazi ya msingi ya Taasisi za tafiti. Hata kama wazo likipatikana kwenye utendaji kazi wa mtaalamu wa afya, wazo husika hutakiwa kusajiriwa kwenye tasisi husika na kuendelezwa chini ya usimamizi mahsusi. Kuna ngazi ikifikiwa ndo kilichovumbuliwa huweza kuja kwenye viwango vya hospitali tena na kundelezwa au kutumika.
Ugunduzi wa molecule/s mpaka kupata dawa ni wastani wa miaka 10-18. Hapo ni pesa inafanya kazi. Kwenye pipeline kuna mawazo mengi, na si yote hufanikiwa kulingana na vigezo mbalimbali.
Kama ungefika kwenye hizi taasisi na kukuta hakuna mawazo ya wataalamu basi tungesema hii shida ni ya wataalamu:
1: National Institute of Medical Research(NIMR) na matawi yake pamoja na kitengo cha tiba asili.
2: Ifakara Health Institute(IHI) na matawi yake.
3: Kilimanjaro Clinical Research Institute(KCRI).
Kutaja kwa chache, kuna makabrasha huko watu wanasubiri pesa na kwa kiasi kikubwa toka kule usikotaka kusikia.
Sisi tumeamua kuwaacha viongizi wetu watembee wamekalia shilingi milioni 250,000-400,000/=, wakati wanaitupatia hela za tafiti wanatembea wamekalia milioni 50,000-100,000/=.
Bado tumeandika policy hizi juu ya thamani ya magari ya viongozi wetu.
Kupanga ni kuchagua, soma kipande hiki kinahusu mabepari wenyewe, je kwetu? 👇
Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees).
Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery.[6]
In 2010, the research and development cost of each new molecular entity was about US$1.8 billion.[7]
In the 21st century, basic discovery research is funded primarily by governments and by philanthropic organizations, while late-stage development is funded primarily by pharmaceutical companies or venture capitalists.[8]
To be allowed to come to market, drugs must undergo several successful phases of clinical trials, and pass through a new drug approval process, called the New Drug Application in the United States.